Quantbot Technologies LP Decreases Stock Holdings in Bruker Corporation $BRKR

Key Points

• Quantbot Technologies LP cut its stake in Bruker by 85.5% in Q3, selling 43,768 shares and ending the period with 7,416 shares worth about $241,000.
• Other large investors ramped up exposure—AQR increased its position to 3.33 million shares (a 125.3% rise) and Orbis Allan Gray opened a new position valued at about $192.7 million—leaving institutional ownership around 79.5% while insiders hold ~27.3%.
• Analyst sentiment is mixed with a MarketBeat consensus "Hold" and $50.38 target; Bruker recently missed EPS ($0.59 vs. $0.65) but topped revenue estimates and set FY2026 guidance of $2.10–$2.15, and it pays a $0.05 quarterly dividend.

Quantbot Technologies LP reduced its position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 85.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 7,416 shares of the medical research company's stock after selling 43,768 shares during the quarter. Quantbot Technologies LP's holdings in Bruker were worth $241,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Orbis Allan Gray Ltd bought a new position in Bruker during the second quarter valued at $192,735,000. AQR Capital Management LLC increased its holdings in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Sculptor Capital LP raised its position in shares of Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company's stock valued at $126,682,000 after buying an additional 476,363 shares in the last quarter. Brown Advisory Inc. lifted its holdings in shares of Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company's stock valued at $113,142,000 after acquiring an additional 336,026 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its holdings in shares of Bruker by 61.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company's stock valued at $67,909,000 after acquiring an additional 796,510 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on BRKR. Rothschild & Co Redburn set a $60.00 price objective on Bruker in a research note on Thursday, November 20th. The Goldman Sachs Group lowered their price objective on Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a research note on Friday, February 13th. Zacks Research upgraded Bruker from a "strong sell" rating to a "hold" rating in a report on Monday, December 8th. Wells Fargo & Company increased their price target on Bruker from $48.00 to $55.00 and gave the company an "overweight" rating in a report on Monday, December 15th. Finally, Barclays lowered their price target on Bruker from $55.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $50.38.

Insiders Place Their Bets

In other news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $49.20, for a total transaction of $98,400.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at approximately $6,319,395.60. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 27.30% of the stock is currently owned by insiders.

Bruker Stock Down 1.6%

Shares of NASDAQ BRKR opened at $36.60 on Wednesday. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $56.22. The firm has a 50-day simple moving average of $44.23 and a two-hundred day simple moving average of $41.09. The company has a market cap of $5.57 billion, a P/E ratio of -244.00, a PEG ratio of 2.23 and a beta of 1.19. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business had revenue of $977.20 million for the quarter, compared to the consensus estimate of $964.61 million. During the same period in the prior year, the company posted $0.76 EPS. The company's quarterly revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker's dividend payout ratio is -133.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.